Novartis India Limited (NOVARTIND.BO)
INR 998.85
(-1.78%)
INR 998.85
(-1.78%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 626.5 Million INR | -7.4% |
| 2022 | 676.6 Million INR | 268.12% |
| 2021 | 183.8 Million INR | 10.32% |
| 2020 | 166.6 Million INR | 451.66% |
| 2019 | 30.2 Million INR | -79.55% |
| 2018 | 147.7 Million INR | 431.17% |
| 2017 | -44.6 Million INR | -117.89% |
| 2016 | 249.3 Million INR | -29.44% |
| 2015 | 353.3 Million INR | 198.65% |
| 2014 | 118.3 Million INR | -82.93% |
| 2013 | 693.2 Million INR | -22.23% |
| 2012 | 891.4 Million INR | -38.55% |
| 2011 | 1.45 Billion INR | -33.75% |
| 2010 | 2.18 Billion INR | 22.36% |
| 2009 | 1.78 Billion INR | 8.93% |
| 2008 | 1.64 Billion INR | 13.15% |
| 2007 | 1.45 Billion INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 234.2 Million INR | 111.56% |
| 2024 Q2 | 173.8 Million INR | -25.79% |
| 2023 Q4 | 110.7 Million INR | -43.26% |
| 2023 FY | 626.5 Million INR | -7.4% |
| 2023 Q2 | 162.6 Million INR | 3.17% |
| 2023 Q3 | 195.1 Million INR | 19.99% |
| 2023 Q1 | 157.6 Million INR | 117.68% |
| 2022 Q2 | 149.4 Million INR | -51.02% |
| 2022 Q3 | 63.4 Million INR | -57.56% |
| 2022 FY | 676.6 Million INR | 268.12% |
| 2022 Q4 | 72.4 Million INR | 14.2% |
| 2022 Q1 | 305 Million INR | 607.66% |
| 2021 Q4 | 43.1 Million INR | 13.12% |
| 2021 FY | 183.8 Million INR | 10.32% |
| 2021 Q1 | 49.3 Million INR | -79.98% |
| 2021 Q2 | 44.1 Million INR | -10.55% |
| 2021 Q3 | 38.1 Million INR | -13.61% |
| 2020 FY | 166.6 Million INR | 451.66% |
| 2020 Q3 | 23 Million INR | -81.9% |
| 2020 Q1 | 80.9 Million INR | -47.6% |
| 2020 Q4 | 246.2 Million INR | 970.43% |
| 2020 Q2 | 127.1 Million INR | 57.11% |
| 2019 Q1 | 24.7 Million INR | -92.37% |
| 2019 Q4 | 154.4 Million INR | 18.4% |
| 2019 FY | 30.2 Million INR | -79.55% |
| 2019 Q2 | 40.8 Million INR | 65.18% |
| 2019 Q3 | 130.4 Million INR | 219.61% |
| 2018 FY | 147.7 Million INR | 431.17% |
| 2018 Q4 | 323.8 Million INR | 34.8% |
| 2018 Q3 | 240.2 Million INR | 87.07% |
| 2018 Q2 | 128.4 Million INR | -29.14% |
| 2018 Q1 | 181.2 Million INR | -79.19% |
| 2017 Q1 | 98.7 Million INR | 30.73% |
| 2017 FY | -44.6 Million INR | -117.89% |
| 2017 Q3 | 257.3 Million INR | -36.3% |
| 2017 Q2 | 403.9 Million INR | 309.22% |
| 2017 Q4 | 870.6 Million INR | 238.36% |
| 2016 Q1 | 297.6 Million INR | 193.15% |
| 2016 Q2 | 339 Million INR | 13.91% |
| 2016 FY | 249.3 Million INR | -29.44% |
| 2016 Q4 | 75.5 Million INR | -64.47% |
| 2016 Q3 | 212.5 Million INR | -37.32% |
| 2015 FY | 353.3 Million INR | 198.65% |
| 2015 Q4 | -319.5 Million INR | -140.4% |
| 2015 Q3 | 790.9 Million INR | -43.39% |
| 2015 Q2 | 1.39 Billion INR | 583.9% |
| 2015 Q1 | 204.3 Million INR | -54.65% |
| 2014 FY | 118.3 Million INR | -82.93% |
| 2014 Q1 | 208.5 Million INR | 137.52% |
| 2014 Q2 | 214.7 Million INR | 2.97% |
| 2014 Q3 | 44.9 Million INR | -79.09% |
| 2014 Q4 | 450.5 Million INR | 903.34% |
| 2013 Q4 | -555.7 Million INR | -356.91% |
| 2013 FY | 693.2 Million INR | -22.23% |
| 2013 Q3 | 216.3 Million INR | 55.39% |
| 2013 Q2 | 139.2 Million INR | -37.55% |
| 2013 Q1 | 222.9 Million INR | 143.62% |
| 2012 Q4 | -511 Million INR | -221.26% |
| 2012 FY | 891.4 Million INR | -38.55% |
| 2012 Q1 | -27 Million INR | -105.63% |
| 2012 Q2 | 584 Million INR | 2262.96% |
| 2012 Q3 | 421.4 Million INR | -27.84% |
| 2011 FY | 1.45 Billion INR | -33.75% |
| 2011 Q2 | 651.8 Million INR | 0.0% |
| 2011 Q3 | 561.2 Million INR | -13.9% |
| 2011 Q4 | 479.2 Million INR | -14.61% |
| 2010 FY | 2.18 Billion INR | 22.36% |
| 2009 FY | 1.78 Billion INR | 8.93% |
| 2008 FY | 1.64 Billion INR | 13.15% |
| 2007 FY | 1.45 Billion INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Ajanta Pharma Limited | 19.67 Billion INR | 96.816% |
| Amrutanjan Health Care Limited | 457.54 Million INR | -36.927% |
| Sigachi Industries Limited | 1.47 Billion INR | 57.494% |
| Bal Pharma Limited | 233.9 Million INR | -167.839% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | 85.828% |
| Medico Remedies Limited | 100.3 Million INR | -524.626% |
| Lasa Supergenerics Limited | -458 Million INR | 236.789% |
| Venus Remedies Limited | 534.65 Million INR | -17.179% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 115.225% |
| Alpa Laboratories Limited | 184.49 Million INR | -239.572% |
| Nectar Lifesciences Limited | 923.8 Million INR | 32.183% |
| Shilpa Medicare Limited | 1.36 Billion INR | 54.145% |
| Aarti Drugs Limited | 7.14 Billion INR | 91.236% |
| Lupin Limited | 28.04 Billion INR | 97.766% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 98.516% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 98.547% |
| Windlas Biotech Limited | 1.29 Billion INR | 51.767% |
| Suven Life Sciences Limited | -1.22 Billion INR | 151.109% |
| Eris Lifesciences Limited | 5.18 Billion INR | 87.909% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 95.614% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 116.26% |
| Ipca Laboratories Limited | 7.98 Billion INR | 92.15% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | 49.106% |
| Achyut Healthcare Limited | 4.43 Million INR | -14016.719% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 99.399% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| RPG Life Sciences Limited | 2.29 Billion INR | 72.669% |
| Mankind Pharma Limited | 21.51 Billion INR | 97.088% |
| Laurus Labs Limited | 3.94 Billion INR | 84.134% |
| Piramal Pharma Limited | 4.55 Billion INR | 86.252% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -151.353% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 97.527% |
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 89.12% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 90.365% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | -9.967% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 86.403% |
| Wockhardt Limited | -670 Million INR | 193.507% |
| Themis Medicare Limited | 392.58 Million INR | -59.582% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | -23.295% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 87.926% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 93.023% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 99.075% |
| Divi's Laboratories Limited | 33.08 Billion INR | 98.106% |
| NATCO Pharma Limited | 25.96 Billion INR | 97.587% |
| Gufic Biosciences Limited | 1.32 Billion INR | 52.892% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | 60.765% |
| Ind-Swift Limited | 1.22 Billion INR | 48.897% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 77.513% |
| FDC Limited | 2.98 Billion INR | 79.02% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 512.288% |
| Granules India Limited | 6.81 Billion INR | 90.809% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Alkem Laboratories Limited | 19.46 Billion INR | 96.781% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | 63.523% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -6808.377% |
| Brooks Laboratories Limited | 14.44 Million INR | -4238.643% |
| Megasoft Limited | -121.1 Million INR | 617.324% |
| ZIM Laboratories Limited | 253.82 Million INR | -146.82% |
| Strides Pharma Science Limited | 5.22 Billion INR | 88.011% |
| Neuland Laboratories Limited | 5.31 Billion INR | 88.219% |
| Morepen Laboratories Limited | 4.17 Billion INR | 84.99% |
| Hikal Limited | 32.11 Million INR | -1851.106% |
| Indoco Remedies Limited | 1.29 Billion INR | 51.53% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 79.972% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -201.13% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -2181.667% |
| Hester Biosciences Limited | 364.81 Million INR | -71.733% |